Navigation Links
Mayo Clinic Finds Capsule Endoscopy Can Detect Intestinal Damage Caused by Celiac Disease
Date:2/27/2008

Study shows extent of intestinal damage does not explain patients' symptoms

ROCHESTER, Minn., Feb. 27 /PRNewswire-USNewswire/ -- Mayo Clinic researchers have found that capsule endoscopy can provide a magnified view of the intestinal damage caused by celiac disease. This new information can help physicians detect and diagnose celiac disease, as well as measure intestinal healing following treatment. These findings are published in this month's issue of Clinical Gastroenterology and Hepatology.

Approximately 3 million Americans, or about one in 100 people, are affected by celiac disease. Individuals who have celiac disease are intolerant to proteins (collectively called gluten) found in wheat, barley and rye grains. In these people, gluten stimulates an immune reaction in the small intestine, which causes intestinal damage and the subsequent inability to absorb certain nutrients from food. Treatment is to avoid foods containing gluten (the so-called gluten-free diet). Untreated, celiac disease can cause many medical complications and increase the risk of death. However, when a medically supervised diet plan is implemented, patients can experience almost complete reversal of symptoms and complications from the disease.

"Capsule endoscopy allows us to look at the entire 30 feet of the small intestine, not just the first one to two feet that can be visualized with other types of endoscopy," says Joseph Murray, M.D., the study's lead author and a gastroenterologist at Mayo Clinic.

The capsule is approximately the size of a large vitamin, and it includes a miniature color video camera, light, battery and transmitter. The patient swallows the capsule, which takes approximately eight hours to move through the small intestine. As the capsule moves through the digestive tract, images recorded by the video camera are transmitted to a number of sensors attached to the patient's torso and recorded digitally on a device worn around the patient's waist. Then, the recording device is removed and its contents are downloaded to a computer for examination.

This study, the first of its kind, used capsule endoscopy to view intestinal damage in 37 patients with untreated, biopsy-proven celiac disease. Ninety-two percent had visible damage detected by capsule endoscopy. Twenty-two patients had extensive damage in the duodenum (first portion of the small intestine) and patchy damage throughout the jejunum (the small intestine's middle portion). Twelve patients had damage limited to the duodenum, and one patient had only patchy damage throughout the jejunum. However, no association was shown between the extent of intestinal damage and the patients' symptoms. Six months after a gluten-free diet was implemented, capsule endoscopy showed improvement, or decreased intestinal damage, in most patients.

"This study confirmed our suspicions that the most extensive intestinal damage in celiac disease patients is primarily to the duodenum. However, we were surprised to discover no correlation between extent of intestine damage and patient symptoms," says Dr. Murray. "Capsule endoscopy will now be another tool to diagnose celiac disease and detect intestinal damage both prior to and following treatment."

Other members of the Mayo Clinic research team included Alberto Rubio Tapia, M.D., Carol Van Dyke, Deanna Brogan, Mary Knipschield, Brian Lahr, Ashwin Rumalla, Alan Zinsmeister, Ph.D., and Christopher Gostout, M.D.

Each year, physicians at Mayo Clinic's campuses in Arizona, Florida and Minnesota treat hundreds of patients who have celiac disease. For more information on celiac disease treatment at Mayo Clinic, visit http://www.mayoclinic.org/celiac-disease/.

To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories.


'/>"/>
SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
2. Treatment of First Patient in Phase I Clinical Trial of Bionomics Anti-Cancer Drug BNC105
3. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
4. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
5. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
6. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
7. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
8. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
9. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
10. Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
11. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/5/2017)... Cincinnati location of Diplomat Specialty Infusion ... been awarded a Top Workplaces 2017 honor by ... on an employee survey administered by WorkplaceDynamics, LLC, a research ... measures several aspects of workplace culture, including alignment, execution, and ... ...
(Date:6/1/2017)... Pa. , June 1, 2017 Nutriceutical ... and Veterinarian Recommended Solutions (VRS), and KD Pharma Group ... in Nutriceutical Holdings by KD Pharma Group. KD Pharma ... with the option to acquire the entire company. ... in KD. They are committed to growing the NH ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... 2017 , ... AMC Health , the leading provider of proven real-time ... market. Similar to its approach in demonstrating positive outcomes in the healthcare market, AMC ... the value of eVisits to support virtual studies. , In a study ...
(Date:6/20/2017)... , ... June 20, 2017 , ... As a leading ... the link between stroke and gum disease. Those with bleeding gums in Vancouver, BC, ... untreated, this condition can lead to heart disease, stroke and diabetes. Drs. Parviz Roshan, ...
(Date:6/20/2017)... ... 20, 2017 , ... Many RNA binding proteins (RBPs) regulate ... team developed expressRNA, a web platform encompassing computational tools for integration of the ... the ‘RNA maps’, which demonstrate that RBPs bind to specific positions on pre-mRNAs ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... agency, recently became re-accredited by the Joint Commission, which accredits and certifies ... and certification is recognized nationwide as a symbol of quality that reflects an ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... her nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, Global ... launched right in to the world’s water crisis and how it affects the ...
Breaking Medicine News(10 mins):